Targeting KRAS in non-small cell lung cancer: recent progress and new approaches - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34089836/
Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS accounts for 85% of...
researchers show that PET/CT images can be used to measure levels of the PD-L1 biomarker of non-small cell lung cancer (NSCLC) patients in a non-invasive manner and, in turn, predict a patient’s response to therapy.
Moffitt Researchers Develop Non-invasive Approach to Measure Biomarker Levels, Predict Outcomes in Lung Cancer Patients
TAMPA, Fla. - Tests that analyze biomarkers are used during cancer management to guide treatment and provide information about patient prognosis. These tests are often performed on tissue biopsy samples...
Guardant 360 FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
...
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen's LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
Source : https://www.businesswire.com/news/home/20210528005396/en/Guardant360
REDWOOD CITY, Calif.--()--Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360 ® CDx test as the first and only liquid biopsy...
-
MICHAEL MISIALEK5yrThe majority of liquid biopsy testing is done without involvement of pathology. I bet my experience is not unique. This is a loss for everyone, representing a missed opportunity for Show More
-
KRAS Oncogene Connect5yrPlease share your thoughts on Guardant 360. In which patients do you plan to use the test?
Sotorasib for Lung Cancers with KRAS p.G12C Mutation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34096690/
In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-mutated NSCLC. (Funded by Amgen and the...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In the current Phase 2 trial published in NEJM, investigators assessed the activity of sotorasib (960 mg PO qd) in patients with KRAS –mutated advanced NSCLC who Show More
Metabolic reprograming of antioxidant defense: a precision medicine perspective for radiotherapy of lung cancer? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34110407/
Radiotherapy plays a key role in the management of lung cancer patients in curative and palliative settings. Traditionally, radiotherapy was either given alone or in combination with surgery, classical cytotoxic...